Phase II Study of BAY 43-9006 in Japanese Patients With Renal Cell Carcinoma
Phase II Study of BAY 43-9006 in Japanese Patients With Renal Cell Carcinoma
To evaluate efficacy, safety, and pharmacokinetics of BAY 43-9006 in patients with unresectable and/or metastatic renal cell cancer (RCC) who have failed at least one cytokine containing regimen.
Inclusion Criteria:
Exclusion Criteria:
Isesaski, Gunma 372-0817, Japan
Kita, Kagawa-ken 761-0793, Japan
Irima-gun, Saitama 350-0495, Japan
Sunto, Shizuoka 411-8777, Japan
Nakakoma, Yamanashi 409-3898, Japan